Speece Thorson Capital Group Inc. raised its position in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 25.5% during the second quarter, HoldingsChannel reports. The firm owned 81,986 shares of the medical equipment provider’s stock after purchasing an additional 16,645 shares during the period. Zimmer Biomet comprises 2.6% of Speece Thorson Capital Group Inc.’s holdings, making the stock its 17th biggest position. Speece Thorson Capital Group Inc.’s holdings in Zimmer Biomet were worth $9,653,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in the business. BlackRock Inc. lifted its holdings in Zimmer Biomet by 3.2% in the 1st quarter. BlackRock Inc. now owns 16,474,877 shares of the medical equipment provider’s stock valued at $2,103,841,000 after purchasing an additional 509,160 shares in the last quarter. OppenheimerFunds Inc. lifted its holdings in Zimmer Biomet by 7.9% in the 1st quarter. OppenheimerFunds Inc. now owns 3,156,333 shares of the medical equipment provider’s stock valued at $403,063,000 after purchasing an additional 231,307 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Zimmer Biomet by 8.4% in the 4th quarter. Geode Capital Management LLC now owns 2,641,717 shares of the medical equipment provider’s stock valued at $273,516,000 after purchasing an additional 205,532 shares in the last quarter. Primecap Management Co. CA lifted its holdings in Zimmer Biomet by 29.4% in the 1st quarter. Primecap Management Co. CA now owns 2,463,720 shares of the medical equipment provider’s stock valued at $314,617,000 after purchasing an additional 559,370 shares in the last quarter. Finally, Boston Partners lifted its holdings in Zimmer Biomet by 61.9% in the 1st quarter. Boston Partners now owns 1,754,479 shares of the medical equipment provider’s stock valued at $224,047,000 after purchasing an additional 670,501 shares in the last quarter. Institutional investors own 88.57% of the company’s stock.
A number of research analysts have weighed in on ZBH shares. Sanford C. Bernstein upgraded Zimmer Biomet from an “underperform” rating to a “market perform” rating and set a $121.71 price objective on the stock in a report on Tuesday, June 11th. Needham & Company LLC upgraded Zimmer Biomet from a “buy” rating to a “strong-buy” rating and lifted their price target for the stock from $146.00 to $155.00 in a report on Wednesday, April 24th. Raymond James lifted their price target on Zimmer Biomet from $145.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, July 29th. Oppenheimer lifted their price target on Zimmer Biomet from $135.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, July 29th. Finally, Robert W. Baird upgraded Zimmer Biomet from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $132.00 to $154.00 in a report on Monday, July 29th. Two analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. Zimmer Biomet presently has an average rating of “Buy” and an average target price of $140.64.
ZBH traded down $0.62 on Friday, hitting $138.31. The company had a trading volume of 880,902 shares, compared to its average volume of 1,486,270. The stock has a market cap of $27.96 billion, a price-to-earnings ratio of 17.90, a P/E/G ratio of 2.43 and a beta of 1.15. Zimmer Biomet Holdings Inc has a 1 year low of $96.99 and a 1 year high of $139.71. The stock’s fifty day simple moving average is $124.80. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.56 and a current ratio of 1.19.
Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Friday, July 26th. The medical equipment provider reported $1.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.02. The firm had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.98 billion. Zimmer Biomet had a negative net margin of 4.56% and a positive return on equity of 13.40%. Zimmer Biomet’s revenue was down .9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.92 EPS. On average, equities research analysts predict that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 31st. Investors of record on Friday, June 28th were issued a $0.24 dividend. The ex-dividend date of this dividend was Thursday, June 27th. This represents a $0.96 annualized dividend and a yield of 0.69%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 12.57%.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Read More: Trading signals using Bollinger bands
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.